Request for Free Sample

Ankylosing Spondylitis Market Report Size Analysis:

The Ankylosing Spondylitis Market was valued at USD 5.77 billion in 2023 and is expected to reach USD 11.15 billion by 2032, growing at a CAGR of 7.59% from 2024 to 2032.

This report offers statistical data and information on the Ankylosing Spondylitis market, including incidence and prevalence trends, giving a wide overview of global and regional disease burden. The report discusses trends in treatment usage, presenting the variations across regions in terms of biologics and therapy adoption. Drug volume and sales trends, and biologic and biosimilar therapy demand tracking are also discussed. In addition, it breaks down healthcare spending by region and considers public and private sources of funds. Finally, the clinical trials and pipeline activity section highlights new therapies in development and research work in the region.

The U.S. Ankylosing Spondylitis Market was valued at USD 2.67 billion in 2023 and is expected to reach USD 5.05 billion by 2032, growing at a CAGR of 7.33% from 2024 to 2032. The United States is a leader in the North American Ankylosing Spondylitis market, led by high usage of biologic therapies, well-developed healthcare infrastructure, and robust pharmaceutical research and development. Further, widespread disease awareness and access to specialist services also strengthen its leading position in the region. The availability of leading market players and supportive regulatory environments also supports accelerated treatment innovation. Recurring investment in clinical trials and patient support programs also adds to the nation's market dominance.

Ankylosing Spondylitis Market Dynamics

Drivers

  • Increasing Adoption of Biologic Therapies is driving the market growth.

The increasing use of biologic therapies is a major growth driver in the Ankylosing Spondylitis (AS) market. Biologics, including tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, have transformed the treatment paradigm, with substantial gains in disease control and patient outcomes. For instance, medications like Humira (adalimumab) and Cosentyx (secukinumab) have demonstrated greater efficacy than conventional disease-modifying anti-rheumatic drugs (DMARDs). In 2023, biologics made up a large percentage of the treatment scenario in the U.S., as biologics are the preferred method of treatment by patients and doctors alike due to their efficacy in lowering inflammation and increasing the quality of life. New biologics coming to market and current clinical trials mean that this trend is expected to become even more powerful, fueling growth in the market.

  • Rising Awareness and Early Diagnosis are propelling the market growth.

Increasing knowledge of Ankylosing Spondylitis, combined with rapid progress in early diagnosis, is another major catalyst. AS usually remains undiagnosed in its early phases because its symptoms are subtle. Nonetheless, more recent awareness initiatives among doctors and patients have translated into enhanced rates of early detection. Imaging procedures, including MRI and X-ray, identify telltale signs of inflammation of the spine and sacroiliac joints that are central in diagnosing AS. Moreover, non-profit and government programs are supporting early screening among vulnerable groups, leading to a higher detection rate. By 2023, early treatment with biologics has been proven to prevent chronic complications, thereby again fueling the need for early diagnosis and treatment.

Restraint

  • High Treatment Costs and Accessibility Issues are restraining the market growth.

One of the principal constraints in the Ankylosing Spondylitis (AS) market is the prohibitive cost of using advanced treatments, especially biologic treatments. Biologics like Humira, Simponi, and Cosentyx are extremely effective, but they carry heavy price tags, usually putting patients off access, especially from countries with fewer healthcare funds or without full insurance coverage. These high prices impose a significant financial burden on patients and healthcare systems alike. Moreover, there tends to be an imbalance in access to such treatment in various geographies, especially in emerging economies and rural regions. Such unavailability of effective therapy prevents best-in-class disease control and potentially causes progression of the disease, thereby restricting market growth overall.

Opportunities

  • Expansion of Biosimilars is creating a significant opportunity for the market.

One of the key opportunities in the Ankylosing Spondylitis market is the growing use of biosimilars. Since the patents on many biologics, such as Humira, have already expired, biosimilars are flooding the market at a quarter of the price of their reference biologics. These substitutes offer effective treatment options while making therapies affordable, particularly in price-sensitive markets. The increasing adoption of biosimilars by regulatory bodies, healthcare professionals, and patients provides a chance for fast market growth. With increased clinical trials and additional regulatory approvals, biosimilars have the potential to influence cost savings and accessibility, making it easier for more patients to access effective treatments and creating future market growth opportunities in the next decade. Also, this transformation provides more competition within the marketplace, increasing even more innovation and patient selection among treatment options.

Challenges

  • Delayed Diagnosis and Disease Progression are challenging the market growth.

One of the major challenges in the Ankylosing Spondylitis market is the late diagnosis and development of the disease. AS is usually diagnosed late because it develops gradually and has nonspecific symptoms, resulting in complications and permanent damage to the spine and joints. Early treatment with biologic drugs is important to control the disease effectively, but most patients are not treated promptly. This diagnostic delay and resultant disease progression enhance the total healthcare cost and diminish the efficacy of treatments. The difficulty is in enhancing diagnostic procedures, raising awareness, and providing early intervention to avoid long-term disability in AS patients. Moreover, lack of proper access to specialized rheumatology services in rural and underserved regions worsens the delay, further affecting patient outcomes and the growth potential of the market.

Ankylosing Spondylitis Market Segmentation Analysis

By Treatment

The Non-steroidal anti-inflammatory drugs (NSAIDs) dominated the Ankylosing Spondylitis (AS) market with a 48.10% market share in 2023 because of their long-standing position as the first-line therapy for the treatment of pain and inflammation related to the disease. NSAIDs like Ibuprofen and Naproxen are commonly prescribed because of their established efficacy in symptom relief, such as the reduction of inflammation, stiffness, and enhancement of mobility. Their over-the-counter (OTC) availability in most areas, lower cost compared to biologic drugs, and rapid symptomatic relief make them the first choice among both patients and physicians. In 2023, even after the emergence of biologic agents, NSAIDs continued to hold sway because they provide quick relief from symptoms, which helps manage disease flare-ups. Moreover, NSAIDs tend to be administered in combination with other drugs, further solidifying their place in the treatment strategy for AS patients.

By Route of Administration

The Parenteral segment dominated the Ankylosing Spondylitis (AS) market with a 57.46% market share in 2023, mainly because of the growing application of biologic drugs delivered via subcutaneous or intravenous injections. These parenteral drugs, including Humira (adalimumab) and Simponi (golimumab), provide excellent efficacy in suppressing inflammation and preventing disease progression, making them the first choice for moderate to severe AS. Biologic therapies are usually more effective parenterally since they need direct entry into the bloodstream for best bioavailability. In 2023, parenteral biologics became the standard of AS management, having the capability to target specific inflammatory pathways such as tumor necrosis factor (TNF) or interleukins. Even though they are more expensive, the better efficacy and long-term disease-modifying effect of parenteral treatments cemented their market leadership role.

By Type

The Prescription drugs segment dominated the ankylosing spondylitis market with a 78.51% market share in 2023 because of the pivotal role prescription treatments have in treating the disease, especially in moderate to severe cases. Medications such as biologics (e.g., Humira, Cosentyx) and disease-modifying anti-rheumatic drugs (DMARDs) are required to control inflammation, avoid damage to joints, and enhance long-term outcomes. These prescription medications are formulated to address the root causes of AS, like immune system impairment, which is not possible with OTC drugs. In 2023, the incidence of more aggressive types of AS, which demand strong prescription treatments, played an important role in the success of this segment. In addition, the increased usage of biologics, in addition to their increased efficacy in treating AS over OTC treatments, solidified the leading status of prescription medication in the marketplace.

By Application

The Adults segment dominated the ankylosing spondylitis market with 88.14% market share in 2023 because AS is more prevalent in adults, especially in the age group of 20 to 40 years. AS targets young to middle-aged adults, and symptoms usually start during early adulthood and continue to worsen over time. Younger adults are more prone to manifesting the chronic, inflammatory character of the disease and thus require long-term treatment. Moreover, adults are more prone to be diagnosed with severe to moderate types of AS, which necessitate higher-level treatment regimens like biologics and DMARDs. The adult population also incurs greater healthcare expenditure because they have longer disease duration and more aggressive treatment patterns. Consequently, the need for specialized therapy and continuous treatment in adults continues to be a driving force in the market's growth.

By Distribution Channel

The Hospital pharmacies segment dominated the ankylosing spondylitis market with a 47.15% market share in 2023, mainly because of the demand for high-cost and specialized treatments that are usually given in hospitals. Biologic drugs, including Humira (adalimumab) and Cosentyx (secukinumab), are usually prescribed to treat moderate to severe AS and need professional administration, monitoring, and follow-up, which is usually offered in hospitals. Hospitals also provide more treatment options, such as intravenous biologics, which have to be administered clinically. Patients with more involved or advanced disease classes also need hospital-based care for disease management, thus increasing the demand for drugs through hospitals. The presence of specialized medical staff and infrastructure in hospitals also makes this channel the most popular among all the channels.

Ankylosing Spondylitis Market Regional Analysis

North America dominated the Ankylosing Spondylitis market with a 56.22% market share in 2023, mainly because of its strong reimbursement systems, high level of disease awareness, and sophisticated healthcare infrastructure. The early adoption of novel biologic therapies and JAK inhibitors for the treatment of ankylosing spondylitis is facilitated by the presence of large biopharmaceutical companies like AbbVie, Johnson & Johnson, and Amgen. The region's leadership is also influenced by the high incidence of inflammatory and autoimmune diseases, as well as the easy access to specialized rheumatology care and diagnostic services. North America's market position is further reinforced by the government's support for autoimmune disease research and the U.S. FDA's steady pipeline approvals.

Asia Pacific is becoming the fastest-growing region with 8.10% CAGR because of rising healthcare costs, growing patient populations, and increased awareness of ankylosing spondylitis. Due to government programs and expanding insurance coverage, nations like China, India, and South Korea are seeing increases in early diagnosis rates and access to cutting-edge biologics. Furthermore, there is a great need for efficient treatments due to the region's sizable population and rising incidence of autoimmune diseases linked to lifestyle choices. In the upcoming years, Asia Pacific is anticipated to see faster market growth as local pharmaceutical companies and biosimilar manufacturers continue to scale up production.

Ankylosing Spondylitis Market Key Players

  • AbbVie Inc. (Humira, Rinvoq)

  • Pfizer Inc. (Xeljanz, Enbrel)
  • Novartis AG (Cosentyx, Voltaren)
  • Johnson & Johnson (Janssen Pharmaceuticals) (Simponi, Remicade)
  • Eli Lilly and Company (Taltz, Olumiant)
  • Amgen Inc. (Enbrel, Otezla)
  • Bristol-Myers Squibb Company (Zeposia, Orencia)
  • UCB S.A. (Cimzia, Bimzelx)
  • Biogen Inc. (Benepali, Imraldi)
  • Roche Holding AG (Actemra, MabThera)
  • Sanofi S.A. (Kevzara, Aubagio)
  • Merck & Co., Inc. (Arcoxia, Remicade - co-marketed)
  • Takeda Pharmaceutical Company Limited (Entyvio, Mobic)
  • Gilead Sciences, Inc. (Jyseleca, Filgotinib)
  • Samsung Bioepis Co., Ltd. (Brenzys, Hadlima)
  • Sun Pharmaceutical Industries Ltd. (Omalizumab, Etoricoxib)
  • Zydus Lifesciences Ltd. (Adalimumab biosimilar, Etoricoxib)
  • Dr. Reddy's Laboratories (Adalimumab biosimilar, Etoricoxib)
  • Hetero Drugs Ltd. (Adalimumab biosimilar, Infliximab biosimilar)
  • Lupin Limited (Etanercept biosimilar, Indomethacin)

Suppliers (These suppliers commonly provide biopharmaceutical manufacturing services, including active pharmaceutical ingredients (APIs), biologics production, and fill-finish services that are essential for monoclonal antibodies, biosimilars, and small molecule drugs used in ankylosing spondylitis treatment.) in the Ankylosing Spondylitis Market

  • Lonza Group AG
  • Boehringer Ingelheim BioXcellence
  • Samsung Biologics
  • WuXi Biologics
  • Fujifilm Diosynth Biotechnologies
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • Siegfried Holding AG
  • Cambrex Corporation
  • Patheon (a part of Thermo Fisher Scientific)

Recent Developments in the Ankylosing Spondylitis Market

  • In October 2024, Johnson & Johnson (J&J) formally announced that it has taken full responsibility for marketing, promoting, and distributing Remicade(R) (infliximab) and Simponi(R) (golimumab) in the United Kingdom. Infliximab is an anti-inflammatory biologic drug used for the treatment of various autoimmune diseases, such as rheumatoid arthritis (RA), Crohn's disease (CD), pediatric CD, ulcerative colitis (UC), pediatric UC, radiographic axial spondyloarthritis (ankylosing spondylitis), psoriatic arthritis (PsA), and plaque psoriasis.

  • In October 2023, Novartis, the global leader in immunodermatology and rheumatology, announced that the U.S. Food and Drug Administration (FDA) had approved the intravenous (IV) formulation of Cosentyx (secukinumab). It is now approved for the treatment of adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA), extending treatment options in patients with such chronic inflammatory conditions.

  • Ankylosing Spondylitis Market Report Scope:
    Report Attributes Details
    Market Size in 2023 US$ 5.77 Billion
    Market Size by 2032 US$ 11.15 Billion
    CAGR CAGR of 7.59 % From 2024 to 2032
    Base Year 2023
    Forecast Period 2024-2032
    Historical Data 2020-2022
    Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
    Key Segments • By Treatment (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Biologic Therapies, JAK Inhibitors, Disease-modifying Anti-rheumatic Drugs (DMARDs), Corticosteroids)
    • By Route of Administration (Parenteral, Oral)
    • By Type (Prescription Drugs, OTC Drugs)
    • By Application (Adults, Juveniles)
    • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America)
    Company Profiles AbbVie Inc., Pfizer Inc., Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals), Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, UCB S.A., Biogen Inc., Roche Holding AG, Sanofi S.A., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Samsung Bioepis Co., Ltd., Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Dr. Reddy's Laboratories, Hetero Drugs Ltd., Lupin Limited, and other players.